 |
| 11-Jan-11 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| 02-Jun-10 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| 16-Feb-10 | Upgrade |
JP Morgan |
Underweight → Neutral |
$26 |
|
| 13-Jan-10 | Downgrade |
Credit Suisse |
Outperform → Underperform |
|
|
| 24-Nov-09 | Initiated |
Leerink Swann |
Mkt Perform |
|
|
| 16-Nov-09 | Initiated |
Deutsche Securities |
Hold |
|
|
| 12-Nov-09 | Initiated |
Barclays Capital |
Equal Weight |
|
|
| 23-Oct-09 | Downgrade |
Jefferies & Co |
Buy → Hold |
|
|
| 17-Mar-09 | Initiated |
Credit Suisse |
Outperform |
|
|
| 26-Jan-09 | Initiated |
Jefferies & Co |
Buy |
|
|
| 14-Nov-08 | Downgrade |
UBS |
Buy → Neutral |
|
|
| 18-Apr-08 | Downgrade |
JP Morgan |
Neutral → Underweight |
|
|
| 11-Feb-08 | Upgrade |
UBS |
Neutral → Buy |
|
|
| 01-Feb-08 | Upgrade |
HSBC Securities |
Underweight → Neutral |
|
|
| 24-Oct-07 | Initiated |
Bernstein |
Mkt Perform |
|
|
| 06-Sep-07 | Initiated |
UBS |
Neutral |
|
|
| 25-Jul-07 | Downgrade |
Bear Stearns |
Peer Perform → Underperform |
|
|
| 25-May-07 | Reiterated |
Banc of America Sec |
Neutral |
$62 → $57 |
|
| 22-May-07 | Downgrade |
Deutsche Securities |
Buy → Hold |
|
|
| 22-Mar-07 | Downgrade |
JP Morgan |
Neutral → Underweight |
|
|
|
|
| 17-May-13 06:33PM | 3 Most Important Upcoming FDA Decisions of 2013 at Motley Fool |
| 11:27AM | The Billion Dollar COPD Deal: Who Gains The Most? at Seeking Alpha |
| 16-May-13 05:05PM | Cheerleaders: Look Beyond Pharma For Jobs YCharts |
| 01:57PM | Time To Show Optimism For Stocks at Seeking Alpha |
| 11:06AM | Prestige Slides On Revenue Miss But Vows More Buys at Investor's Business Daily |
| 15-May-13 01:42PM | Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companies at Motley Fool |
| 01:31PM | Amicus Therapeutics: The Good And The Bad at Seeking Alpha |
| 01:28PM | Is Vivus a Buy at These Prices? at Wall St. Cheat Sheet |
| 10:08AM | Is AstraZeneca Gearing Up for a Shopping Spree? at Motley Fool |
| 09:24AM | Aveo Screwed Up but Its Kidney Cancer Drug Is Real at TheStreet |
| 09:12AM | Dirty Medicine at Fortune |
| 07:55AM | 3 Pharmaceuticals For Attractive Dividends at Seeking Alpha |
| 14-May-13 04:00PM | Elan in Royalty Deal with THRX Zacks |
| 02:16PM | Should You Buy Stock in Gilead After the Earnings Miss? at Motley Fool |
| 10:15AM | Wider-than-Expected Loss at ChemoCentryx Zacks |
| 10:00AM | GlaxoSmithKline PLC Stock Buy Recommendation Reiterated (GSK) at TheStreet |
| 08:44AM | Who Benefits From This Market Moving Biotechnology Partnership? at Motley Fool |
| 13-May-13 08:58PM | Generic Drug Maker Pleads Guilty in Federal Case at New York Times |
| 08:58PM | Generic Drug Maker Pleads Guilty in Federal Case at New York Times |
| 05:40PM | Diversifying Royalties at a Hefty Cost at Motley Fool |
| 05:30PM | Theravance, Glaxo, Elan Star In Biotech Soap Opera at Investor's Business Daily |
| 05:20PM | Glaxo/THRX's Breo Ellipta Gets FDA Nod Zacks |
| 04:28PM | Why Did This Biotech Soar? at Motley Fool |
| 04:25PM | On The Fly: Closing Wrap at theflyonthewall.com |
| 04:07PM | A Breather for a Day, as Health Care Stocks Do the Heavy Lifting at New York Times |
| 01:40PM | Why Theravance Shares Soared Again at Motley Fool |
| 12:20PM | On The Fly: Midday Wrap at theflyonthewall.com |
| 12:07PM | GSK, Shell lead U.K. stocks to 8th day of gains at MarketWatch |
| 12:00PM | Speculation Sickens the Dow, Pharma Tries to Cure It at Motley Fool |
| 11:16AM | Theravance Stock Hits High On $1 Billion Elan Deal at Investor's Business Daily |
| 09:41AM | [video] Faber Report: Elan Strikes Deal With Theravance at CNBC |
| 09:40AM | 3 FTSE 100 Shares Hitting New Highs: GlaxoSmithKline, BT Group, British American Tobacco at Motley Fool |
| 09:06AM | Invest In Greece Because The Turnaround Has Already Started at Seeking Alpha |
| 12-May-13 06:13PM | A Closer Look at GlaxoSmithKline's Dividend Potential at Motley Fool |
| 06:06PM | Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company? at Seeking Alpha |
| 11-May-13 11:30AM | This Week in Biotech at Motley Fool |
| 11:00AM | Some Fish Oil Doesn't Help Some Patients in Some Countries at Motley Fool |
| 06:06AM | [$$] Where European Investors Look for Value at Barrons.com |
| 10-May-13 04:02PM | Why Theravance Shareholders Can Breathe Easier at Motley Fool |
| 03:59PM | BREO ELLIPTA gains US approval for the treatment of COPD PR Newswire |
| 02:21PM | No Fat in This Drug Launch at Motley Fool |
| 01:22PM | Theravance, Glaxo Stocks Rise On Lung Drug Approval at Investor's Business Daily |
| 12:37PM | BREO(TM) ELLIPTA(TM) Gains US Approval for the Treatment of COPD Marketwired |
| 12:37PM | BREO(TM) ELLIPTA(TM) Gains US Approval for the Treatment of COPD Marketwire |
| 11:42AM | Marketing Without Innovation: a Merck Story YCharts |
| 11:30AM | 4 Buy-Rated Dividend Stocks: HME, GSK, EPR, HPT at TheStreet |
| 11:15AM | FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease theflyonthewall.com |
| 10:40AM | What's Missing in This Market TheStreet |
| 06:53AM | GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says theflyonthewall.com |
| 04:00AM | Upcoming Catalysts Could Push ChemoCentryx To Double In 2013 at Seeking Alpha |
| 09-May-13 10:02PM | Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived at Seeking Alpha |
| 06:07PM | Pharmas Failure: Drug Spending Finally Declines YCharts |
| 05:53PM | Drugmakers, health groups bring poor girls vaccine AP |
| 02:28PM | Drugmakers, health groups bring poor girls vaccine AP |
| 12:30PM | Another Negative Fish Oil Study Adds To Amarin's Marketing Challenges at Investopedia |
| 11:48AM | Drug Firms Find New Way to Shorten Clinical Trials Big Data Download |
| 11:48AM | Drug Firms Find New Way to Shorten Clinical Trials |
| 11:05AM | Sarepta's Meaningless Q1 Results at Motley Fool |
| 09:52AM | Avanir Reports Strong Revenue but Misses on Earnings at Motley Fool |
| 09:04AM | Drugmakers, health groups bring poor girls vaccine AP |
| 08:27AM | Merck And Glaxo Drop HPV Vaccine Price To Reach Girls In The Developing World at Forbes |
| 08:27AM | Great News: HPV Vaccine Prices Drop To Reach Girls In The Developing World at Forbes |
| 07:36AM | Drugmakers, health groups bring poor girls vaccine AP |
| 08-May-13 05:45PM | Isis Reports In-Line Loss Zacks |
| 05:00PM | Another Disappointing Study For Fish Oil Supplements at Forbes |
| 07-May-13 12:47PM | Imminent Catalysts For Small Pharmaceuticals at Seeking Alpha |
| 10:50AM | Buy Individual Stocks Instead of Dividend ETFs at Motley Fool |
| 10:45AM | Wider-than-Expected Loss at Dynavax Zacks |
| 09:53AM | GlaxoSmithKline Stock To Go Ex-dividend Tomorrow (GSK) at TheStreet |
| 08:14AM | Looking For Real Viagra? Head to the Internet. at Motley Fool |
| 08:12AM | Small Companies Are Leading Innovation For New Drugs To Treat Depression at Forbes |
| 06-May-13 10:32AM | Shorts Are Piling Into These Stocks. Should You Be Worried? at Motley Fool |
| 09:36AM | Cost Cutting Initiative to Bolster GlaxoSmithKline's Earnings at Motley Fool |
| 09:25AM | Netupitant Results Could Roil Tesaro In May at Seeking Alpha |
| 08:40AM | Even Pharma's Good Deeds Are Criticized at Forbes |
| 05-May-13 04:00PM | Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players at Motley Fool |
| 02:30PM | Take a Deep Breath Before This Big FDA Decision at Motley Fool |
| 12:01PM | Can Johnson & Johnson Deal With This Publicity Fiasco? at Wall St. Cheat Sheet |
| 04-May-13 03:45AM | Buffett's Long-Term, High-Dividend Plays at TheStreet |
| 03-May-13 11:47AM | Faster Drug Approval Process Results as Consequence of Closer Collaboration Between Drug Manufacturers and the FDA: Learn Which Antibiotic Companies Are Benefiting in this Exclusive Interview Wall Street Transcript |
| 09:30AM | This May Be The Best Pharmaceutical Stock for Income Investors StreetAuthority Network |
| 09:30AM | This May Be The Best Pharmaceutical Stock for Income Investors |
| 08:35AM | 3 FTSE 100 Shares Going Ex-Dividend Next Week at Motley Fool |
| 02-May-13 04:30PM | Glaxo's Trametinib Delayed Zacks |
| 04:06PM | Athersys Has Some Promise, But Controversy And Doubt Remain at Seeking Alpha |
| 09:16AM | Opko Health CEO Buys 45K Shares and 4 Insider Trades to Note at Wall St. Cheat Sheet |
| 08:50AM | Impax Beats Earnings Estimate Zacks |
| 08:28AM | 3 Pharma Stocks to Buy for the Long Run at Motley Fool |
| 01-May-13 09:14PM | Take 2 Dividend Stocks and Call Me in the Morning at Motley Fool |
| 08:53PM | Glaxo Mined Online Parent Discussion Boards For Vaccine Worries at The Wall Street Journal |
| 08:46PM | Why America Is Suing This Pharmaceutical Behemoth at Motley Fool |
| 06:09PM | Big Pharma's Kickback Conundrum at Motley Fool |
| 11:48AM | Four Companies that Are Better to Invest in Than Amazon at Motley Fool |
| 11:30AM | 3 Buy-Rated Dividend Stocks at TheStreet |
| 08:56AM | Is All Well With These 4 Pharmaceutical Powerhouses? at Motley Fool |
| 08:54AM | Merck Softens A Lower 2013 Profit Forecast With $15B Stock Buyback at Forbes |
| 30-Apr-13 04:53PM | Is GlaxoSmithKline an Exciting Emerging Market Play? at Motley Fool |
| 04:47PM | 3 Pharmaceutical Companies Awaiting FDA Approval, Part II at Seeking Alpha |
| 03:48PM | Are Dividend Yields the Cure for Pharma Investors' Woes? at Motley Fool |
| 03:45PM | Glaxo-Impax End Rytary Deal Zacks |
|
|
| GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also produces paediatric and adult vaccines to prevent a range of infectious diseases, including hepatitis A and B; diphtheria, tetanus, and whooping cough; measles, mumps, and rubella; polio; typhoid; influenza; and bacterial meningitis. In addition, it provides consumer health products in oral care, nutritional, total wellness, and skin health areas. The company's total wellness products include Panadol for the treatment of paracetamol-based treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; ENO Tums, a rapid relief antacid; and oral care products comprise Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to improve comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. Its nutrition products include Lucozade for energy and hydration; and Horlicks and Maxinutrition for nutrition; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| GLAXOSMITHKLINE PLC | 10% Owner | Apr 30 | Buy | 6699215.43 | 193,563 | 1,296,720,236,277 | 26,721,193 | Apr 30 02:38 PM | | GLAXOSMITHKLINE PLC | 10% Owner | Feb 15 | Buy | 22.03 | 116,527 | 2,567,090 | 26,527,630 | Feb 20 03:04 PM | | GLAXOSMITHKLINE PLC | 10% Owner | Nov 02 | Buy | 22.35 | 280,348 | 6,265,778 | 26,411,103 | Nov 05 01:38 PM | | GLAXOSMITHKLINE PLC | 10% Owner | Aug 03 | Buy | 28.21 | 316,334 | 8,923,782 | 26,130,755 | Aug 07 12:54 PM | | GLAXOSMITHKLINE PLC | Director | Aug 02 | Buy | 14.25 | 62,646,186 | 892,708,151 | 233,716,708 | Aug 03 04:26 PM | | GLAXOSMITHKLINE PLC | Director | Aug 01 | Buy | 14.25 | 5,686,715 | 81,035,689 | 171,070,522 | Aug 03 04:26 PM | | GLAXOSMITHKLINE PLC | Director | Aug 01 | Buy | 14.25 | 1,788,186 | 25,481,651 | 165,383,807 | Aug 01 05:28 PM | | GLAXOSMITHKLINE PLC | Director | Jul 30 | Buy | 14.25 | 4,934,743 | 70,320,088 | 163,595,621 | Aug 01 05:28 PM |
|
|
|
|
|
|
